197 related articles for article (PubMed ID: 31181234)
1. Mammalian legumain - A lysosomal cysteine protease with extracellular functions?
Lunde NN; Bosnjak T; Solberg R; Johansen HT
Biochimie; 2019 Nov; 166():77-83. PubMed ID: 31181234
[TBL] [Abstract][Full Text] [Related]
2. Design of cell-permeable, fluorescent activity-based probes for the lysosomal cysteine protease asparaginyl endopeptidase (AEP)/legumain.
Sexton KB; Witte MD; Blum G; Bogyo M
Bioorg Med Chem Lett; 2007 Feb; 17(3):649-53. PubMed ID: 17189693
[TBL] [Abstract][Full Text] [Related]
3. The Mammalian Cysteine Protease Legumain in Health and Disease.
Solberg R; Lunde NN; Forbord KM; Okla M; Kassem M; Jafari A
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555634
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and evaluation of aza-peptidyl inhibitors of the lysosomal asparaginyl endopeptidase, legumain.
Lee J; Bogyo M
Bioorg Med Chem Lett; 2012 Feb; 22(3):1340-3. PubMed ID: 22243962
[TBL] [Abstract][Full Text] [Related]
5. Proteolysis mediated by cysteine cathepsins and legumain-recent advances and cell biological challenges.
Brix K; McInnes J; Al-Hashimi A; Rehders M; Tamhane T; Haugen MH
Protoplasma; 2015 May; 252(3):755-74. PubMed ID: 25398648
[TBL] [Abstract][Full Text] [Related]
6. Structure and function of legumain in health and disease.
Dall E; Brandstetter H
Biochimie; 2016 Mar; 122():126-50. PubMed ID: 26403494
[TBL] [Abstract][Full Text] [Related]
7. Biosynthetic processing of cathepsins and lysosomal degradation are abolished in asparaginyl endopeptidase-deficient mice.
Shirahama-Noda K; Yamamoto A; Sugihara K; Hashimoto N; Asano M; Nishimura M; Hara-Nishimura I
J Biol Chem; 2003 Aug; 278(35):33194-9. PubMed ID: 12775715
[TBL] [Abstract][Full Text] [Related]
8. Cysteine cathepsins: Their biological and molecular significance in cancer stem cells.
Pišlar A; Jewett A; Kos J
Semin Cancer Biol; 2018 Dec; 53():168-177. PubMed ID: 30063965
[TBL] [Abstract][Full Text] [Related]
9. Legumain/asparaginyl endopeptidase controls extracellular matrix remodeling through the degradation of fibronectin in mouse renal proximal tubular cells.
Morita Y; Araki H; Sugimoto T; Takeuchi K; Yamane T; Maeda T; Yamamoto Y; Nishi K; Asano M; Shirahama-Noda K; Nishimura M; Uzu T; Hara-Nishimura I; Koya D; Kashiwagi A; Ohkubo I
FEBS Lett; 2007 Apr; 581(7):1417-24. PubMed ID: 17350006
[TBL] [Abstract][Full Text] [Related]
10. Asparagine endopeptidase is an innovative therapeutic target for neurodegenerative diseases.
Zhang Z; Xie M; Ye K
Expert Opin Ther Targets; 2016 Oct; 20(10):1237-45. PubMed ID: 27115710
[TBL] [Abstract][Full Text] [Related]
11. Nuclear legumain activity in colorectal cancer.
Haugen MH; Johansen HT; Pettersen SJ; Solberg R; Brix K; Flatmark K; Maelandsmo GM
PLoS One; 2013; 8(1):e52980. PubMed ID: 23326369
[TBL] [Abstract][Full Text] [Related]
12. An asparaginyl endopeptidase processes a microbial antigen for class II MHC presentation.
Manoury B; Hewitt EW; Morrice N; Dando PM; Barrett AJ; Watts C
Nature; 1998 Dec; 396(6712):695-9. PubMed ID: 9872320
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in the development of legumain-selective chemical probes and peptide prodrugs.
Poreba M
Biol Chem; 2019 Nov; 400(12):1529-1550. PubMed ID: 31021817
[TBL] [Abstract][Full Text] [Related]
14. A protease-responsive fluorescent probe for sensitive imaging of legumain activity in living tumor cells.
Li X; Liu Q; Ye S; Wang S; Li K; Lv G; Peng Y; Qiu L; Lin J
Chem Biol Drug Des; 2019 Aug; 94(2):1494-1503. PubMed ID: 31002467
[TBL] [Abstract][Full Text] [Related]
15. Mice lacking asparaginyl endopeptidase develop disorders resembling hemophagocytic syndrome.
Chan CB; Abe M; Hashimoto N; Hao C; Williams IR; Liu X; Nakao S; Yamamoto A; Zheng C; Henter JI; Meeths M; Nordenskjold M; Li SY; Hara-Nishimura I; Asano M; Ye K
Proc Natl Acad Sci U S A; 2009 Jan; 106(2):468-73. PubMed ID: 19106291
[TBL] [Abstract][Full Text] [Related]
16. Importance of lysosomal cysteine proteases in lung disease.
Wolters PJ; Chapman HA
Respir Res; 2000; 1(3):170-7. PubMed ID: 11667982
[TBL] [Abstract][Full Text] [Related]
17. Lysosomal cysteine proteases: more than scavengers.
Turk B; Turk D; Turk V
Biochim Biophys Acta; 2000 Mar; 1477(1-2):98-111. PubMed ID: 10708852
[TBL] [Abstract][Full Text] [Related]
18. Papain-like cysteine proteases.
Brömme D
Curr Protoc Protein Sci; 2001 May; Chapter 21():Unit 21.2. PubMed ID: 18429163
[TBL] [Abstract][Full Text] [Related]
19. Lansoprazole inhibits the cysteine protease legumain by binding to the active site.
Bosnjak T; Solberg R; Hemati PD; Jafari A; Kassem M; Johansen HT
Basic Clin Pharmacol Toxicol; 2019 Aug; 125(2):89-99. PubMed ID: 30916878
[TBL] [Abstract][Full Text] [Related]
20. Expression of the cysteine protease legumain in vascular lesions and functional implications in atherogenesis.
Clerin V; Shih HH; Deng N; Hebert G; Resmini C; Shields KM; Feldman JL; Winkler A; Albert L; Maganti V; Wong A; Paulsen JE; Keith JC; Vlasuk GP; Pittman DD
Atherosclerosis; 2008 Nov; 201(1):53-66. PubMed ID: 18377911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
